Difference between revisions of "Part:BBa K3904405"
Bernadeta A (Talk | contribs) |
Bernadeta A (Talk | contribs) |
||
(7 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
− | + | <partinfo>BBa_K3904405 short</partinfo> | |
Line 7: | Line 7: | ||
[[File:T--Vilnius-Lithuania--amebyeLogo dark.png|right|100px|AmeBye]] | [[File:T--Vilnius-Lithuania--amebyeLogo dark.png|right|100px|AmeBye]] | ||
− | Vilnius-Lithuania iGEM 2021 project [https://2021.igem.org/Team:Vilnius-Lithuania <b>AmeBye</b>]looks at amebiasis holistically and comprehensively, | + | Vilnius-Lithuania iGEM 2021 project [https://2021.igem.org/Team:Vilnius-Lithuania <b>AmeBye</b>]looks at amebiasis holistically and comprehensively, therefore target <i>E. histolytica</i> from several angles: prevention and diagnostics. Our team's preventive solution consists of probiotics engineered to produce naringenin - an antiprotozoal compound. Two strains of genetically modified microorganisms were chosen as the main chassis - world-renowned <i>Lactobacillus casei</i> BL23 (<i>Lactobacillus paracasei</i>) and <i>Escherichia coli</i> Nissle 1917. Furthermore, the team made specific gene deletions to enhance naringenin production and adapted a novel toxin-antitoxin system to prevent GMO spreads into the environment. The diagnostic part includes a rapid, point of care, user-friendly diagnostic test identifying extraintestinal amebiasis. The main components of this test are aptamers specific to the <i>E. histolytica</i> secreted proteins. These single-stranded DNA sequences fold into tertiary structures for particular fit with target proteins. |
__TOC__ | __TOC__ | ||
Line 13: | Line 13: | ||
=Usage and Biology= | =Usage and Biology= | ||
− | CRISPR-Cas9 is a versatile genome-editing technique. In our approach to editing <i>E. coli</i> Nissle 1917 genome, we have used two plasmid based system enabling to combine of Lambda Red recombination and CRISPR-Cas9 as counterselection tools | + | CRISPR-Cas9 is a versatile genome-editing technique. In our approach to editing <i>E. coli</i> Nissle 1917 genome, we have used two plasmid based system enabling to combine of Lambda Red recombination and CRISPR-Cas9 as counterselection tools encoded in [https://www.addgene.org/62225/ pCas] and [https://www.addgene.org/62226/ pTarget]. |
==Mechanism of genome editing== | ==Mechanism of genome editing== | ||
+ | |||
+ | [[File:T--Vilnius-Lithuania--crisprcas92.png|right|500px|CRISPRCas9]] | ||
pCas plasmid is used for Cas9, Lambda Red system expression, and plasmid curing of pTarget. Cas9 - the RNA-guided endonuclease - is expressed constitutively, while the expression of Lambda Red genes (Gam, Exo, Beta) is under the control of arabinose inducible promoter araBp. pTarget plasmid caries constitutively expressed single-guide RNA (sgRNA). This RNA molecule, as and in nature, is composed of 17-20 nt length guide RNA (gRNA) sequence complementary to the targeted DNA adjacent to the protospacer adjacent motif (PAM) present at the 3' end, and the scaffold for the Cas9 nuclease binding to sgRNA and forming the ribonucleoprotein complex (1). Although in nature sgRNA exists as two separate RNA molecules, in laboratory experiments they are usually combined into one single-guide RNA (sgRNA) obviating additional maturation steps. As both pCas and pTarget plasmids are in a cell, Cas9 nuclease and sgRNA are able to form ribonucleoprotein complex, scan DNA for PAM sequences and perform a double-strand break in a part of the DNA which is complementary to the gRNA and adjacent to the PAM sequence - NGG. However, if arabinose has been added to the cell culture and a double-stranded DNA repair template is present in the cell, the Lambda Red system performs homologous recombination. If this process is unsuccessful, the Cas9-sgRNA complex will cause a double-strand break and will cause cell death (2). This is employed as a counterselection in order to avoid the additional antibiotic as selection marker usage. | pCas plasmid is used for Cas9, Lambda Red system expression, and plasmid curing of pTarget. Cas9 - the RNA-guided endonuclease - is expressed constitutively, while the expression of Lambda Red genes (Gam, Exo, Beta) is under the control of arabinose inducible promoter araBp. pTarget plasmid caries constitutively expressed single-guide RNA (sgRNA). This RNA molecule, as and in nature, is composed of 17-20 nt length guide RNA (gRNA) sequence complementary to the targeted DNA adjacent to the protospacer adjacent motif (PAM) present at the 3' end, and the scaffold for the Cas9 nuclease binding to sgRNA and forming the ribonucleoprotein complex (1). Although in nature sgRNA exists as two separate RNA molecules, in laboratory experiments they are usually combined into one single-guide RNA (sgRNA) obviating additional maturation steps. As both pCas and pTarget plasmids are in a cell, Cas9 nuclease and sgRNA are able to form ribonucleoprotein complex, scan DNA for PAM sequences and perform a double-strand break in a part of the DNA which is complementary to the gRNA and adjacent to the PAM sequence - NGG. However, if arabinose has been added to the cell culture and a double-stranded DNA repair template is present in the cell, the Lambda Red system performs homologous recombination. If this process is unsuccessful, the Cas9-sgRNA complex will cause a double-strand break and will cause cell death (2). This is employed as a counterselection in order to avoid the additional antibiotic as selection marker usage. | ||
Line 21: | Line 23: | ||
− | == | + | <b>Table 1.</b> sgRNA collection for <i>E. coli</i> Nissle 1917 genome editing. |
+ | |||
+ | {| class="wikitable" | ||
+ | |- | ||
+ | |ackA-specific sgRNA | ||
+ | |[https://parts.igem.org/Part:BBa_K3904401 BBa_K3904401] | ||
+ | |- | ||
+ | ||pta-specific sgRNA | ||
+ | |[https://parts.igem.org/Part:BBa_K3904402 BBa_K3904402] | ||
+ | |- | ||
+ | |colicin-specific sgRNA | ||
+ | |[https://parts.igem.org/Part:BBa_K3904405 BBa_K3904405] | ||
+ | |- | ||
+ | |nupG-specific sgRNA | ||
+ | |[https://parts.igem.org/Part:BBa_K3904426 BBa_K3904426] | ||
+ | |} | ||
+ | |||
+ | |||
+ | |||
+ | <b>Table 2.</b> Parts collection for genomic insertion into <i>E. Coli</i> Nissle 1917 <i>colicin</i> gene. | ||
+ | |||
+ | {| class="wikitable" | ||
+ | |- | ||
+ | |<b>Short description</b> | ||
+ | |<b>Part number</b> | ||
+ | |- | ||
+ | |colicin-specific sgRNA | ||
+ | |[https://parts.igem.org/Part:BBa_K3904405 BBa_K3904405] | ||
+ | |- | ||
+ | |Forward primer to generate a right homology arm of <i>colicin</i> gene | ||
+ | |[https://parts.igem.org/Part:BBa_K3904411 BBa_K3904411] | ||
+ | |- | ||
+ | |Reverse primer to generate right homology arm of <i>colicin</i> gene | ||
+ | |[https://parts.igem.org/Part:BBa_K3904410 BBa_K3904410] | ||
+ | |} | ||
+ | |||
+ | ==colicin-specific sgRNA importance to our project== | ||
+ | |||
+ | Particularly in our project, we needed to insert the metabolic pathway for naringenin production into the genomes of our target probiotic strains. We have chosen two genomic sites for genomic insertions, which would do not harm or negatively affect our probiotic bacteria growth or overall performance - a putative colicin-encoding and <i>nupG</i> genes. We have inserted sfGFP encoding gene under the control of constitutive slpA promoter into these sequences. SfGFP fluorescence was significantly higher in samples with insertion in <i>nupG</i>, however, this case also demonstrated higher fluorescence fluctuations in comparison with putative colicin samples. | ||
+ | |||
+ | [[File:T--Vilnius-Lithuania--positioning.png|center|500px|CRISPRCas9]] | ||
+ | |||
+ | <b>Fig. 1.</b> Transcriptional activity comparison of GFP transcription from its constructs insertion in <i>nupG</i> or <i>colicin</i> genes. | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | ==Genome editing efficiency== | ||
+ | |||
+ | GFP insertion into <i>colicin</i> gene with this sgRNA have be have achieved with 89 % efficiency (fig. 2). | ||
+ | |||
+ | [[File:T--Vilnius-Lithuania--GFP-colicin.png|left|500px|CRISPRCas9]] | ||
+ | |||
+ | <b>Fig. 2.</b> GFP insertion into <i>colicin</i> gene results. Here are represented with XbaI digested cPCR products from chosen transformant colonies. If insertion is successful, 1 kbp and 148 bp products are expected. L - GeneRuler 1 bkp Ladder, 1 - negative control (wild type <i>E. coli</i> Nissle 1917), 2 - <i>colicin</i> wild type, 3 - <i>colicin</i>-GFP mutant, 4 - <i>colicin</i>-GFP mutant, 5 - <i>colicin</i>-GFP mutant, 6 - <i>colicin</i>-GFP mutant, 7 - <i>colicin</i>-GFP mutant, 8 - <i>colicin</i>-GFP mutant, 9 - <i>colicin</i>-GFP mutant, 10 - <i>colicin</i>-GFP mutant. | ||
+ | |||
+ | |||
+ | |||
+ | |||
Line 36: | Line 95: | ||
<li>Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213).</li> | <li>Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213).</li> | ||
<li>Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013). RNA-guided human genome engineering via Cas9. Science (New York, N.Y.), 339(6121), 823–826.</li> | <li>Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013). RNA-guided human genome engineering via Cas9. Science (New York, N.Y.), 339(6121), 823–826.</li> | ||
− | |||
− | |||
− | |||
</ol> | </ol> | ||
<!-- --> | <!-- --> |
Latest revision as of 01:35, 22 October 2021
colicin-specific sgRNA
Introduction
Vilnius-Lithuania iGEM 2021 project AmeByelooks at amebiasis holistically and comprehensively, therefore target E. histolytica from several angles: prevention and diagnostics. Our team's preventive solution consists of probiotics engineered to produce naringenin - an antiprotozoal compound. Two strains of genetically modified microorganisms were chosen as the main chassis - world-renowned Lactobacillus casei BL23 (Lactobacillus paracasei) and Escherichia coli Nissle 1917. Furthermore, the team made specific gene deletions to enhance naringenin production and adapted a novel toxin-antitoxin system to prevent GMO spreads into the environment. The diagnostic part includes a rapid, point of care, user-friendly diagnostic test identifying extraintestinal amebiasis. The main components of this test are aptamers specific to the E. histolytica secreted proteins. These single-stranded DNA sequences fold into tertiary structures for particular fit with target proteins.
Contents
Usage and Biology
CRISPR-Cas9 is a versatile genome-editing technique. In our approach to editing E. coli Nissle 1917 genome, we have used two plasmid based system enabling to combine of Lambda Red recombination and CRISPR-Cas9 as counterselection tools encoded in pCas and pTarget.
Mechanism of genome editing
pCas plasmid is used for Cas9, Lambda Red system expression, and plasmid curing of pTarget. Cas9 - the RNA-guided endonuclease - is expressed constitutively, while the expression of Lambda Red genes (Gam, Exo, Beta) is under the control of arabinose inducible promoter araBp. pTarget plasmid caries constitutively expressed single-guide RNA (sgRNA). This RNA molecule, as and in nature, is composed of 17-20 nt length guide RNA (gRNA) sequence complementary to the targeted DNA adjacent to the protospacer adjacent motif (PAM) present at the 3' end, and the scaffold for the Cas9 nuclease binding to sgRNA and forming the ribonucleoprotein complex (1). Although in nature sgRNA exists as two separate RNA molecules, in laboratory experiments they are usually combined into one single-guide RNA (sgRNA) obviating additional maturation steps. As both pCas and pTarget plasmids are in a cell, Cas9 nuclease and sgRNA are able to form ribonucleoprotein complex, scan DNA for PAM sequences and perform a double-strand break in a part of the DNA which is complementary to the gRNA and adjacent to the PAM sequence - NGG. However, if arabinose has been added to the cell culture and a double-stranded DNA repair template is present in the cell, the Lambda Red system performs homologous recombination. If this process is unsuccessful, the Cas9-sgRNA complex will cause a double-strand break and will cause cell death (2). This is employed as a counterselection in order to avoid the additional antibiotic as selection marker usage.
Table 1. sgRNA collection for E. coli Nissle 1917 genome editing.
ackA-specific sgRNA | BBa_K3904401 |
pta-specific sgRNA | BBa_K3904402 |
colicin-specific sgRNA | BBa_K3904405 |
nupG-specific sgRNA | BBa_K3904426 |
Table 2. Parts collection for genomic insertion into E. Coli Nissle 1917 colicin gene.
Short description | Part number |
colicin-specific sgRNA | BBa_K3904405 |
Forward primer to generate a right homology arm of colicin gene | BBa_K3904411 |
Reverse primer to generate right homology arm of colicin gene | BBa_K3904410 |
colicin-specific sgRNA importance to our project
Particularly in our project, we needed to insert the metabolic pathway for naringenin production into the genomes of our target probiotic strains. We have chosen two genomic sites for genomic insertions, which would do not harm or negatively affect our probiotic bacteria growth or overall performance - a putative colicin-encoding and nupG genes. We have inserted sfGFP encoding gene under the control of constitutive slpA promoter into these sequences. SfGFP fluorescence was significantly higher in samples with insertion in nupG, however, this case also demonstrated higher fluorescence fluctuations in comparison with putative colicin samples.
Fig. 1. Transcriptional activity comparison of GFP transcription from its constructs insertion in nupG or colicin genes.
Genome editing efficiency
GFP insertion into colicin gene with this sgRNA have be have achieved with 89 % efficiency (fig. 2).
Fig. 2. GFP insertion into colicin gene results. Here are represented with XbaI digested cPCR products from chosen transformant colonies. If insertion is successful, 1 kbp and 148 bp products are expected. L - GeneRuler 1 bkp Ladder, 1 - negative control (wild type E. coli Nissle 1917), 2 - colicin wild type, 3 - colicin-GFP mutant, 4 - colicin-GFP mutant, 5 - colicin-GFP mutant, 6 - colicin-GFP mutant, 7 - colicin-GFP mutant, 8 - colicin-GFP mutant, 9 - colicin-GFP mutant, 10 - colicin-GFP mutant.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
References
- Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213).
- Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013). RNA-guided human genome engineering via Cas9. Science (New York, N.Y.), 339(6121), 823–826.